Trial reportNature communications2019
Outcomes of controlled human malaria infection after BCG vaccination.
Trial report in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 142 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Novel Use of an Existing Vaccine (BCG) Alliance: The NUEVA Trial
Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly (PARITIE)
Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity
Who cites it
142 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An integrative genomics approach identifies KDM4 as a modulator of trained immunity.European journal of immunology · 2022Pooled it
- Six Weeks of Baker's Yeast β-Glucan Supplementation Reveals Unique Immune Maturation mRNA Signature: Implications for Immunity?International journal of molecular sciences · 2026Trial
- The influence of neonatal BCG vaccination on in vitro cytokine responses to Plasmodium falciparum.BMC immunology · 2024Trial
- Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.The New England journal of medicine · 2023Trial
- Trial
- Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes.Cell reports. Medicine · 2022Trial
- Efficacy and Safety of BCG Revaccination WithFrontiers in immunology · 2022Trial
- Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of β-Glucans and Selenium- and Zinc-EnrichedNutrients · 2021Trial
- The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.The Lancet. Infectious diseases · 2021Trial
- Neonatal BCG Vaccination Reduces Interferon-γ Responsiveness to Heterologous Pathogens in Infants From a Randomized Controlled Trial.The Journal of infectious diseases · 2020Trial
- Seasonal variation in the non-specific effects of BCG vaccination on neonatal mortality: three randomised controlled trials in Guinea-Bissau.BMJ global health · 2020Trial
- Activatory Receptor NKp30 Predicts NK Cell Activation During Controlled Human Malaria Infection.Frontiers in immunology · 2019Trial
- Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics.Current opinion in HIV and AIDS · 2026Review
- The case for exploring innate memory in Plasmodium infection.Current opinion in microbiology · 2026Review
- Trained immunity modulators: A new frontier in immunoregulation and disease intervention.Journal of advanced research · 2026Review
- A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2.NPJ vaccines · 2026Article
- A new mRNA antigen vaccine induces potent B and T cell responses andbioRxiv : the preprint server for biology · 2026Article
- Review
- Agent-specific training directs distinctive immune response againstFrontiers in immunology · 2026Article
- Bibliometric and Visual Analysis of Trained Immunity from 2005 to 2024.Journal of inflammation research · 2026Review
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Recent evidence suggests that certain vaccines, including Bacillus-Calmette Guérin (BCG), can induce changes in the innate immune system with non-specific memory characteristics, termed 'trained immunity'. Here we present the results of a randomised, controlled phase 1 clinical trial in 20 healthy male and female volunteers to evaluate the induction of immunity and protective efficacy of the anti-tuberculosis BCG vaccine against a controlled human malaria infection. After malaria challenge infection, BCG vaccinated volunteers present with earlier and more severe clinical adverse events, and have significantly earlier expression of NK cell activation markers and a trend towards earlier phenotypic monocyte activation. Furthermore, parasitemia in BCG vaccinated volunteers is inversely correlated with increased phenotypic NK cell and monocyte activation. The combined data demonstrate that BCG vaccination alters the clinical and immunological response to malaria, and form an impetus to further explore its potential in strategies for clinical malaria vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.